AVE Science & Technology Co Ltd (688067) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AVE Science & Technology Co Ltd (688067) has a cash flow conversion efficiency ratio of 0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥15.02 Million ≈ $2.20 Million USD) by net assets (CN¥518.37 Million ≈ $75.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688067 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
AVE Science & Technology Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how AVE Science & Technology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AVE Science & Technology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AVE Science & Technology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Central Omega Resources Tbk PT
JK:DKFT
|
0.283x |
|
The Gold Bond Group Ltd
TA:GOLD
|
0.012x |
|
Supermax Corporation Bhd
KLSE:7106
|
0.001x |
|
Microtek International Inc
TW:2305
|
0.027x |
|
Community Bancorp. Common Stock
NASDAQ:CMTV
|
0.035x |
|
Old Point Financial Corporation
NASDAQ:OPOF
|
0.014x |
|
St Augustine Gold and Copper Ltd
TO:SAU
|
-0.002x |
|
Chen Full International Co Ltd
TWO:8383
|
0.144x |
Annual Cash Flow Conversion Efficiency for AVE Science & Technology Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of AVE Science & Technology Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 688067 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥495.85 Million ≈ $72.56 Million |
CN¥22.41 Million ≈ $3.28 Million |
0.045x | -2.60% |
| 2023-12-31 | CN¥489.84 Million ≈ $71.68 Million |
CN¥22.73 Million ≈ $3.33 Million |
0.046x | -25.87% |
| 2022-12-31 | CN¥475.12 Million ≈ $69.52 Million |
CN¥29.74 Million ≈ $4.35 Million |
0.063x | -36.65% |
| 2021-12-31 | CN¥477.58 Million ≈ $69.88 Million |
CN¥47.19 Million ≈ $6.90 Million |
0.099x | -50.17% |
| 2020-12-31 | CN¥236.72 Million ≈ $34.64 Million |
CN¥46.93 Million ≈ $6.87 Million |
0.198x | -19.38% |
| 2019-12-31 | CN¥252.51 Million ≈ $36.95 Million |
CN¥62.10 Million ≈ $9.09 Million |
0.246x | +32.38% |
| 2018-12-31 | CN¥217.27 Million ≈ $31.79 Million |
CN¥40.36 Million ≈ $5.91 Million |
0.186x | +42.49% |
| 2017-12-31 | CN¥189.95 Million ≈ $27.80 Million |
CN¥24.76 Million ≈ $3.62 Million |
0.130x | -25.67% |
| 2016-12-31 | CN¥177.84 Million ≈ $26.02 Million |
CN¥31.19 Million ≈ $4.56 Million |
0.175x | +21.23% |
| 2015-12-31 | CN¥147.53 Million ≈ $21.59 Million |
CN¥21.35 Million ≈ $3.12 Million |
0.145x | -14.61% |
| 2014-12-31 | CN¥138.28 Million ≈ $20.24 Million |
CN¥23.43 Million ≈ $3.43 Million |
0.169x | +38.06% |
| 2013-12-31 | CN¥121.15 Million ≈ $17.73 Million |
CN¥14.87 Million ≈ $2.18 Million |
0.123x | -6.50% |
| 2012-12-31 | CN¥103.11 Million ≈ $15.09 Million |
CN¥13.53 Million ≈ $1.98 Million |
0.131x | -- |
About AVE Science & Technology Co Ltd
AVE Science&Technology CO.,LTD researches, develops, manufactures, markets, and services medical devices, biological reagents, remote medical diagnosis network, computer software, automatic control devices, and medical auxiliary equipment China, Europe, the United States, Asia, Africa, and internationally. The company offers urine formed elements analyzer and related reagents, automatic urine ana… Read more